Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
The Effectiveness of rTMS in Depressed VA Patients
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
- Trial name
- NCT01191333
- Testing
- rTMS
- Where
- 9 sites in United States
- Volunteers
- 164 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression - Major Depressive Disorder
Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)
To determine the bioequivalence of 2 tablets of 25 mg sustained release (SR) formulation of DVS and 1 tablet of 50 mg SR formulation of DVS under fed and fast conditions.
- Trial name
- NCT01190514
- Testing
- desvenlafaxine succinate sustained release
- Where
- Belgium
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Major Depression
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
The antidepressant medications are among the most commonly prescribed pharmacological agents in patients with mood and anxiety disorder.
- Trial name
- NCT03927950
- Testing
- escitalopram, bupropion
- Where
- Estonia
- Volunteers
- 135 people
- Sponsor
- University of Tartu
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Pain, Postoperative, Depression, Postpartum
Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)
The purpose of this study is to identify a tolerable dose for postpartum ketamine infusion using a maximum tolerated dose (MTD) 3+3 design.
- Trial name
- NCT05907213
- Testing
- Ketamine (Ketalar) Dose Level 1, Ketamine (Ketalar) Dose Level 2, Ketamine (Ketalar) Dose Level 3
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Grace Lim, MD, MS
Affective Disorders, Psychotic, Depressive Disorder
Treatment of Psychotic Major Depression With Mifepristone
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.
- Trial name
- NCT00867360
- Testing
- Mifepristone (RU-486)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depression, Major Depressive Disorder
Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
The goal of this proposal is to conduct the first pilot study of whether consuming flavanol supplements will augment the cognitive and mood benefits of antidepressant medication in older adults with Late LifeDepression (LLD).
- Trial name
- Flavanol (NCT02943096)
- Testing
- CocoaVia
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
- Trial name
- MIRAI (NCT04770285)
- Testing
- CT-152 - Digital Therapeutic
- Where
- United States
- Volunteers
- 386 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Unipolar
Ketamine + Mindfulness for Depression
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises…
- Trial name
- NCT05168735
- Testing
- Intravenous Ketamine, Brief Mindfulness Exercises, Academic Exercises
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Rebecca Price
Major Depressive Disorder
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
- Trial name
- NCT03188185
- Testing
- ALKS 5461
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 278 people
- Sponsor
- Alkermes, Inc.
Depression, Depressive Disorder, Major
An Expert System to Reduce Depression in Primary Care
The purpose of this study is to determine whether a home-based intervention matched to stage of change (readiness) for using effective methods to prevent or reduce depression can improve depression outcomes in primary care.
- Trial name
- NCT00497874
- Testing
- Computer-tailored intervention
- Where
- 2 sites in United States
- Volunteers
- 902 people
- Sponsor
- Pro-Change Behavior Systems
Alcohol Use Disorder, Depressive Disorder
Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans
The purpose of this study is to evaluate the efficacy of intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) as a treatment for Veterans with an alcohol use disorder (AUD) to decrease the exceedingly high…
- Conditions
- Alcohol Use Disorder, Depressive Disorder, Cigarette Smoking
- Trial name
- NCT03291431
- Testing
- Intermittent theta burst transcranial magnetic stimulation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences